Evonik élargit ses capacités d'administration de médicaments à base de lipides grâce à une nouvelle installation de fabrication conforme aux BPF à Vancouver

Positive

AI Analysis

Summary

Evonik is expanding its lipid-based drug delivery capabilities with a new GMP-compliant manufacturing facility in Vancouver, investing over 150 million CAD to meet growing demand for lipid nanoparticle development and clinical trial manufacturing.

Importance:4/10

Sentiment:

0.60

manufacturinglipid nanoparticlescapacity expansionGMP compliancedrug delivery

Read the original article

Published by PR Newswire Biotech on August 28, 2026 7:50 PM

Read Original